NRx Pharmaceuticals
NRXP · Nasdaq · United States
Share price · NRXP
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when NRXP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+14.3%
- Day beforeEarnings date (period ending 2026-09-30)
- 17 Nov 2026+14.0%
- 4 Nov 2026+11.2%
Nothing announced by NRXP that day or the session before.
- 30 Oct 2026-14.7%
Nothing announced by NRXP that day or the session before.
- 22 Oct 2026-8.7%
Nothing announced by NRXP that day or the session before.
- 7 Aug 2026+15.9%
- 26 May 2026+33.9%
Nothing announced by NRXP that day or the session before.
- 20 Apr 2026+25.5%
Nothing announced by NRXP that day or the session before.
- 24 Mar 2026+20.3%
- 16 Mar 2026+11.8%
Nothing announced by NRXP that day or the session before.
Share of unusual movement by asset
For each asset, the share of NRXP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 23% |
| Sessions with no dated event | — | 77% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | NMDA receptor (glycine site) + dopamine/5-HT receptorSmall molecule | Major Depressive DisorderBipolar Depression |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.1M | $2.1M | $27M | $17M-$8.9M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $1.1M | $1.3M | — | $1.4M-$4.3M operating cash flow | report ↗ |
| 2025-Q3 | $0.2M | $1.4M | — | $5.9M-$2.9M operating cash flow | report ↗ |
| 2025-Q2 | — | $1.0M | — | $18M-$4.0M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $0.8M | — | $5.5M-$3.5M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $0.6M | — | $1.6M-$2.3M operating cash flow | report ↗ |
| 2024-Q2 | — | $2.8M | — | $7.9M-$2.6M operating cash flow | report ↗ |
| 2024-Q1 | — | $1.8M | $1.3M | $6.5M-$3.7M operating cash flow | report ↗ |
| 2023-Q3 | — | $3.3M | $8.9M | $6.1M-$4.6M operating cash flow | report ↗ |
| 2023-Q2 | — | $3.9M | $15M | $8.7M-$7.8M operating cash flow | report ↗ |
| 2023-Q1 | — | $3.6M | $17M | $11M-$6.1M operating cash flow | report ↗ |
| 2022-Q3 | — | $4.1M | $18M | $9.1M-$6.3M operating cash flow | report ↗ |
| 2022-Q2 | — | $3.0M | $25M | $7.0M-$15M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.5M | $40M | $13M-$10M operating cash flow | report ↗ |
| 2021-Q3 | — | $6.3M | $39M | $21M-$12M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.2M | $3.8M | — | $7.2M-$14M operating cash flow | report ↗ |
NRx Pharmaceuticals reported revenue of $1.23M for fiscal 2025 versus $0M in the prior year, with R&D spend of $3.78M, down 39.0% YoY. Cash and equivalents were not disclosed, and the company reported a net loss of $28.62M with a quarterly net burn of $28.62M.
The 10-K highlights clinical-stage CNS programs, including KETAFREE, for which the company received an FDA preliminary determination of no bioequivalence deficiency and plans to initiate commercial sales with FDA approval in Q3 2026; NRX-100, for which an NDA is expected to be filed in Q2 2026 under FDA Fast Track designation; and NRX-101, an oral candidate in development. The company also noted its role as founder and majority owner of HOPE Therapeutics, which provides interventional psychiatry care for treatment-resistant depression and PTSD.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-28 | Javitt Jonathan C · director, CEO and Chairman | Award / grant (derivative) | 150,000 | — | — | Form 4 |
| 2026-07-28 | ABRAMS MICHAEL S · Chief Financial Officer | Award / grant (derivative) | 75,000 | — | — | Form 4 |
| 2026-01-27 | Casper Joseph Michael · Chief Operating Officer | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2025-04-09 | Flynn Patrick John · director | Award / grant (derivative) | 50,000 | — | — | Form 4 |
| 2025-04-09 | Hurvitz Chaim · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2025-04-09 | McBride Dennis · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2025-04-09 | Javitt Jonathan C · director, Chairman and Chief Scientist, 10% owner | Award / grant (derivative) | 125,000 | — | — | Form 4 |
| 2025-02-07 | ABRAMS MICHAEL S · Chief Financial Officer | Award / grant (derivative) | 50,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 32 reporting institutions held 6.2M shares ($13.1M, 14.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | B Group, Inc. | 3,000,000 | $6.4M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,160,184 | $2.5M |
| 3 | AdvisorShares Investments LLC | 420,467 | $896K |
| 4 | COMMONWEALTH EQUITY SERVICES, LLC | 397,431 | $847K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 310,112 | $661K |
| 6 | VANGUARD FIDUCIARY TRUST CO | 169,580 | $361K |
| 7 | Bleakley Financial Group, LLC | 117,204 | $250K |
| 8 | BlackRock, Inc. | 98,995 | $211K |
| 9 | STATE STREET CORP | 86,984 | $185K |
| 10 | XTX Topco Ltd | 78,733 | $168K |
| 11 | Chicago Partners Investment Group LLC | 34,479 | $102K |
| 12 | JANE STREET GROUP, LLC | 44,152 | $94K |
| 13 | NORTHERN TRUST CORP | 43,469 | $93K |
| 14 | Headlands Technologies LLC | 39,394 | $84K |
| 15 | AXQ CAPITAL, LP | 33,211 | $71K |